NCT04705831View on ClinicalTrials.gov

Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

March 30, 2024

Study Completion Date

July 1, 2024

Conditions
Post-Viral Fatigue SyndromePost-Viral Disorder (Disorder)Covid19
Interventions
DRUG

Ruconest

C1 Esterase Inhibitor

Trial Locations (1)

80112

IMMUNOe Research Centers, Centennial

Sponsors
All Listed Sponsors
lead

IMMUNOe Research Centers

INDUSTRY

NCT04705831 - Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection | Biotech Hunter | Biotech Hunter